RE: RE: RE: RE: Bladder Cancer 545M per year
Those are my numbers based on my analysis of Biotech sector.,
45% is a given for manufacturing cost.
Bioniche will make a profit while manufacturing so margin is usually about 50% but I assume 33%.
So 10-15% of sale price= profit for BNC.
Full valuation will be given in 2-3 months to BNC as if PIII was ready for approval as soon as we get PIIIa results.
BNC has already SPA , fast track.
So market will assume FDA approval upon first result.
I saw the trial design. Failure risk is rather low.
I was quite impressed with the CR (complete response)
I am new to BNC so DD might be incorrect.
20M upon signature not include in 110M... that's good to know. thanks.
I think there is enough momentum to push to 2$ in anticipation of good news.
Even 3$ is possible just on momentum.
Trial has been lasting for so long that positive outcome must have already leak out from patient to market participant.
That's why we are seeing this runnup.